Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) - A Small-Cap Biotech with Big Upside!
🔬 Tackling HFpEF, a multi-billion-dollar market with limited treatment options.
💊 CRD-38 could be a first-in-class therapy, making Cardiol a prime acquisition target for pharma giants.
📈 Analysts bullish-H.C. Wainwright maintains a Buy rating & $9.00 price target!
💲 Currently trading at $1.17 USD, with major growth potential as clinical trials advance.

#BiotechStocks #HFpEF #CRD38 #GrowthStocks #CardiolTherapeutics #StockMarket